Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk by Ganz, Tomas et al.
ReviewIron Administration, Infection, and Anemia
Management in CKD: Untangling the Effects
of Intravenous Iron Therapy on Immunity and Infection
Risk
Tomas Ganz, George R. Aronoff, Carlo A.J.M. Gaillard,
Lawrence T. Goodnough, Iain C. Macdougall, Gert Mayer, Graça Porto,








© 2020 The Authors.
Published by Elsevier Inc.
on behalf of the National
Kidney Foundation, Inc. This
is an open access article
under the CC BY-NC-ND
license (http://
creativecommons.org/
licenses/by-nc-nd/4.0/).Patients with chronic kidney disease (CKD) are at increased risk for infection, attributable to im-
mune dysfunction, increased exposure to infectious agents, loss of cutaneous barriers, comorbid
conditions, and treatment-related factors (eg, hemodialysis and immunosuppressant therapy).
Because iron plays a vital role in pathogen reproduction and host immunity, it is biologically
plausible that intravenous iron therapy and/or iron deficiency influence infection risk in CKD.
Available data from preclinical experiments, observational studies, and randomized controlled trials
are summarized to explore the interplay between intravenous iron and infection risk among patients
with CKD, particularly those receiving maintenance hemodialysis. The current evidence base,
including data from a recent randomized controlled trial, suggests that proactive judicious use of
intravenous iron (in a manner that minimizes the accumulation of non–transferrin-bound iron)
beneficially replaces iron stores while avoiding a clinically relevant effect on infection risk. In the
absence of an urgent clinical need, intravenous iron therapy should be avoided in patients with
active infection. Although serum ferritin concentration and transferrin saturation can help guide
clinical decision making about intravenous iron therapy, definition of an optimal iron status and its
precise determination in individual patients remain clinically challenging in CKD and warrant
additional study.INTRODUCTION
Iron is required for both pathogen reproduction and host
immunity, and in healthy individuals, iron homeostasis is
tightly regulated. In chronic kidney disease (CKD), iron
homeostasis is disordered as a result of increased iron
losses, reduced iron absorption, and disruptions in iron
storage and mobilization.1 Systemic iron homeostasis can
be further affected by the administration of intravenous
(IV) iron, a common practice in the management of renal
anemia. In the United States, more than three-quarters of
hemodialysis (HD) patients have received IV iron in the
prior 3 months.2 Although most patients with non-
–dialysis-dependent CKD demonstrate evidence of iron
deficiency,3 IV iron use is infrequent (w10%) among
these patients.4
It is recognized that “imbalances of iron homeostasis
can affect the risk for, and the outcome of, infec-
tions”5(p32) but the clinical impact of therapeutic iron on
this risk remains unclear. Whereas administration of IV
iron has been implicated as a potential risk factor
contributing to increased infection risk in CKD by some
sources,6,7 clinical evidence supporting such an association
is currently lacking. At the Kidney Disease: Improving
Global Outcomes (KDIGO) Controversies Conference on
Iron Management in CKD in 2014, participants noted that
much of the available data were derived from observa-
tional trials and that evidence examining an associationKidney Med Vol 2 | Iss 3 | May/June 2020between IV iron use and infection was “conflicting” and
“inconclusive.”5
To that end, an international multidisciplinary group of
experts was convened to examine available evidence and
provide practical guidance for the use of IV iron in CKD
with regard to infection risk. The meeting was sponsored by
Vifor Fresenius Medical Care Renal Pharma, which manu-
factures several iron replacement therapies. Based on dis-
cussions at the meeting, this review examines the interplay
between IV iron and infection risk among patients with
CKD, particularly those receiving maintenance HD. We re-
view laboratory data on the impact of iron administration
on pathogen infectivity/virulence/growth and immune cell
function. We examine potential lessons from other disease
states before summarizing data from observational and
randomized controlled trials (RCTs) conducted in CKD
populations. Finally, we discuss evidence gaps and practical
considerations for today’s clinical practice.
Although the authors examined the published literature
critically, we did not perform a formal systematic review or
formally grade the quality of evidence. Whereas this article
examines the potential association between iron and infection
risk, the reader is reminded that appropriate use of IV iron
requires a balanced consideration of all of the associated
benefits (eg, impact on anemia, heart failure, and cardiovas-
cular outcomes) and risks (eg, allergic reaction and iron
accumulation).341
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Figure 1. Factors contributing to increased risk for infection and infection-related morbidity in chronic kidney disease (CKD).6,7,16-20
Abbreviation: GI, gastrointestinal.
ReviewINFECTION IN CKD
Infections are a leading contributor of morbidity and mor-
tality among patients with CKD. They are the second most
common cause of death in patients with end-stage kidney
disease, and compared with the general population, patients
receiving maintenance HD are approximately 100-fold more
likely to die of sepsis.8,9 Such findings likely result from
increased susceptibility to infection and impaired recovery
from established infections. The increased risk for infection
associated with CKD is not limited to patients with more
advanced disease; patients with relatively preserved kidney
function (eg, CKD stage 2) experience significant increases in
infection-related hospitalization.10,11 In addition to more
frequent infection-related hospitalization, the average length
of stay for such admissions is nearly 10-fold longer than for
the general population.12 The hospitalization rate among HD
patients in the United States has remained similar from 2006
through 2016.8
Beyond the direct effects of infection, data suggest an
interplay between infection and cardiovascular events.
As observed in non-CKD populations,13 infectious
episodes predict increased risk for subsequent cardio-
vascular events in patients with advanced CKD (ie,
estimated glomerular filtration rate of 15-45 mL/min/
1.73 m2).14 In the Canadian Study of Prediction of Risk
and Evolution to Dialysis, Death and Interim Cardio-
vascular Events Over Time (CanPREDDICT), infection
(ie, positive culture, use of antibiotics, or hospitalization
for infection) was associated with 80% and 220% in-
creases in risk for subsequent cardiovascular ischemia
and congestive heart failure, respectively (median
follow-up, 3.5 years).14 Similarly, in the Proactive IV
Iron Therapy in Haemodialysis Patients (PIVOTAL) trial,
there was a strong association between a first cardio-
vascular event and an infectious episode in the month
leading up to the event (hazard ratio [HR], 2.83; 95%
confidence interval [CI], 2.04-3.92).15342The association between CKD and increased infection
risk is well established and appears to result from mul-
tiple contributing factors (Fig 1).6,7,16-20 Among patients
with CKD not requiring dialysis, urinary tract infections
and pneumonia represented the second and third
most common causes of hospitalization, respectively, and
were 59% and 49% higher in patients with CKD
compared with patients without CKD.21 In contrast, in a
retrospective review of patients receiving maintenance
dialysis, vascular access device infections and skin and soft
tissue infections (including below-the-knee infections)
accounted for nearly 50% of infections.22 In the same
study, cultures identified Gram-positive cocci (eg, staph-
ylococci) and aerobic Gram-negative rods (eg, Pseudomonas
aeruginosa and Escherichia coli) in 48% and 35% of infections,
respectively. Patients with end-stage kidney disease are
also at significantly increased risk for developing active
tuberculosis.23 In addition, patients are at increased risk
from viral and fungal infections. In one study, patients
with CKD were more than 17 times more likely than the
general population to be hospitalized for influenza.24
IRON’S VITAL ROLE IN CELLULAR FUNCTION,
INFECTION, AND IMMUNITY
The ability of iron to donate and accept electrons permits it
to function in reactions that contribute to energy pro-
duction, oxygen transport, and DNA synthesis.25,26 Inad-
equate iron can lead to impaired cellular growth and cell
death.25 In contrast, an excess of iron can also lead to cell
injury secondary to the formation of hydroxyl or lipid
radicals.25,26 To control the amount of iron available to
cells and prevent a toxic excess or deficit, iron is tightly
regulated. Several proteins function as iron chaperones to
prevent “free” or unbound iron from forming destructive
radicals or being easily obtained by pathogens.27 These
proteins are all considered acute-phase reactants and their
concentrations are affected by infection and/orKidney Med Vol 2 | Iss 3 | May/June 2020



























Reviewinflammation (Table 1).26-29 Iron is released from trans-
porting or storage cells (ie, enterocytes, macrophages, and
hepatocytes) exclusively through the iron exporter ferro-
portin. Iron export is tightly regulated through modulation
of production of the hormone hepcidin such that higher
levels of hepcidin are associated with reduced iron export
from storage cells.30 As explored next, blood hepcidin
concentration is increased in the setting of inflammation,
infection, and IV iron administration, thereby restricting
iron export.1
Iron is also required for growth of virtually all human
pathogens.26,27 As such, many pathogens have evolved
elegant mechanisms to evade our physiologic iron-
withholding mechanisms and successfully “steal” iron.
Some organisms have developed means for capturing free
iron, whereas others can acquire protein-bound iron. Side-
rophores, secreted iron chelators, can bind iron with higher
affinity than many chaperone proteins.26,27 Extracellular
bacteria can also obtain iron through heme acquisition (ie,
direct heme uptake systems and hemophore-dependent
systems), endocytosis of transferrin or lactoferrin mole-
cules through membrane-bound receptors, and ferric/
ferrous iron transporters.26 Fungi can acquire iron through
similar mechanisms, and some fungi even use ferric re-
ductases to dissociate iron from chelators.26 Intracellular
bacteria can acquire iron from host cells by using side-
rophores, by direct acquisition of host cytoplasmic iron,
and/or by affecting host cell homeostasis to increase iron
availability inside phagosomes.26 Finally, viruses also require
iron for propagation and can acquire it by altering host-cell
iron homeostasis, in some cases by altering cellular pro-
cessing of iron, leading to relative iron loading within cells.31
Because iron is necessary for cellular growth and
reproduction, strategies that restrict or limit pathogen ac-
cess to iron can serve as an effective arm of innate im-
munity. This “nutritional immunity” relies on a number of
host mechanisms to restrict iron availability.26,28 Infection
triggers a rapid reduction in plasma iron concentration.32
Much of this hypoferremic response results from an in-
crease in hepcidin level triggered by inflammatoryKidney Med Vol 2 | Iss 3 | May/June 2020cytokines, particularly interleukin 6 (IL-6).27,28 Whereas
hepcidin is a major contributor to hypoferremia, non-
–hepcidin-dependent mechanisms have also been identi-
fied.28,33,34 Lactoferrin, found in milk, mucosal secretions,
and sweat, binds iron at mucosal surfaces. It is also released
within neutrophils and can bind to and retain iron in
acidic environments, suggesting that it may be effective
after a clinical infection has already started.26-28,34 Animal
studies confirm the importance of lactoferrin in preventing
skin infections by Staphylococcus aureus.35
As part of an immune strategy to limit iron acquisition
by pathogens, lipocalin 2 (also referred to as siderocalin
and neutrophil gelatinase–associated lipocalin) can be
released by neutrophils, macrophages, and epithelial cells
to bind and eliminate some microbial siderophores.26,28,34
Whereas hepcidin-induced retention of iron in macro-
phages is seemingly beneficial in preventing infections
with extracellular pathogens,28 such a strategy could
potentially be counterproductive for prevention of in-
fections caused by Mycobacterium tuberculosis, an intracellular
bacterium that reproduces in macrophage phagosomes.
Alterations in cell membrane–bound transferrin receptors
and ferroportin expression that may reduce iron avail-
ability have been documented in macrophages following
infection with M tuberculosis.26,36,37 The immune system
also uses iron to catalyze the generation of reactive oxygen
species by phagocytes that can directly lead to oxidative
damage of pathogens. Reactive oxygen species have also
been implicated in a number of nonoxidative immune
mechanisms.38LABORATORY EVIDENCE EXAMINING IRON
AVAILABILITY AND RISK FOR INFECTION
Given that pathogen growth, host growth, and host im-
munity all require cellular access to iron, the net effect of
increased iron availability can only be understood by
examining the effects of “extra” iron on pathogen growth
and the immune system. Experimental data have demon-
strated that the growth of a number of pathogenic fungi,
bacteria, viruses, and protozoa is stimulated by increased
availability of iron.39,40 These findings extend to common
causes of infectious disease (eg, Escherichia species, staphy-
lococci, and mycobacteria) and pathogens less commonly
encountered in clinical practice (eg, Vibrio species). In
animal studies, IV administration of various forms of iron
(eg, lysed red blood cells and iron dextran) has also been
associated with increased virulence of many bacterial
pathogens.41 However, the effect of iron on the virulence
of bacterial species appears to vary by subtype/strain. This
suggests an inconsistent evolutionary benefit of such iron-
dependent growth strategies.42
Murine models have demonstrated that genetic ablation
of hepcidin is associated with increased risk for infection,
but the effect is largely limited to extracellular Gram-
negative infections (Yersinia enterocolitica, Vibrio vulnificus, Kleb-
siella pneumoniae, and E coli).28,43-46 In similar studies,343
Reviewhepcidin deficiency did not appear to increase the risk for
infection associated with S aureus (Gram positive) or M
tuberculosis (intracellular).44 In models of hepcidin defi-
ciency, the increased risk for infection/bacterial growth
observed with some Gram-negative bacteria appears to
result from accumulation of non–transferrin-bound
iron.28,44-46
The association between non–transferrin-bound iron
levels and Gram-negative bacterial growth has been
confirmed in several studies. Stefanova et al45 observed that
the presence/absence of non–transferrin-bound iron in
human plasma was a determinant of E coli growth. In an
ex vivo experiment, Cross et al47 demonstrated that the
growth of E coli, Y enterocolitica, and Salmonella typhimurium in
serum collected after oral iron supplementation correlated
with transferrin saturation (TSAT) levels.47 In that study,
mean TSAT after iron administration was 75.7%47;
non–transferrin-bound iron is generally detectable when
TSAT is >75%.48 Finally, a strong linear relationship between
non–transferrin-bound iron levels and the growth of a
pathogenic strain of E coli in serum collected after transfusion
of “older” red blood cells (ie, 40-42 days of storage) was
observed among healthy volunteers.49 Data regarding the
impact of supplemental iron on the growth of bacteria that
spend at least part of their life cycle intracellularly (eg, M
tuberculosis and S typhimurium) are conflicting.50
Given the variety of specialized immune cells, it is not
surprising that experimental increases in iron concentra-
tion and availability appear to have differential effects on
cells of the innate and adaptive immune systems. Evidence
from in vitro and in vivo studies indicates that iron
overload is preferentially associated with anomalies in T-
lymphocyte function and the relative expansions of the 2
major T-cell populations (ie, CD8+ and CD4+).51,52 In
return, selective T-lymphocyte defects influence the pro-
gression of iron overload.53,54 In rats, iron overload results
in expansion of suppressor/cytotoxic T cells (CD8+) rela-
tive to T-helper (CD4+) cells.55 Similar imbalances in T-
cell sets have been observed in patients with beta thalas-
semia major, such that increased numbers of CD8+ T
lymphocytes correlate with increasing numbers of blood
transfusions.56 Within the category of T-helper cells, the
helper T cell type 1 subset, responsible for the production
of interferon γ and tumor necrosis factor β, which activate
macrophages, are more sensitive to changes in iron
levels.34 In turn, as macrophage iron levels increase, there
is inhibition of interferon γ–mediated pathways.34,41 The
net result of these changes is a potential for impaired
immunity against intracellular bacteria. Increased iron
levels have also been associated with impaired neutrophil
phagocytic function and M1 polarization of macro-
phages.57-59 Although a complete review of the immu-
nologic effects of iron deficiency is beyond the scope of
this review, iron deficiency appears to have immunosup-
pressive effects. Specifically, iron deficiency has been
associated with impaired cell-mediated immune response
and reduced CD4+ T-cell counts, reduced antibody344concentrations, and reduced expression of some cytokines
(eg, IL-2 and IL-6).60,61
KDIGO recommendations against the use of IV iron in
patients with active systemic infection are supported by
experimental data.5 IV iron administration in control
animals resulted in oxidative stress, a modest inflamma-
tory state, and no mortality, but the administration of
iron in septic animals resulted in a mortality rate of
w60%.62LESSONS FROM INHERITED IRON
DISORDERS
In HD patients, and less so among non–dialysis-dependent
patients with CKD and peritoneal dialysis patients, IV iron
is commonly administered on an ongoing basis, a practice
that may place patients in a chronic state of positive iron
balance.1 As such, we endeavored to examine the risk for
infection in other conditions associated with increased
total-body iron stores. Mutations in HFE, a gene encoding a
major histocompatibility complex I–like protein that
modulates hepcidin expression, account for most cases of
hereditary hemochromatosis.63 Patients with HFE-associ-
ated hemochromatosis (Online Mendelian Inheritance in
Man [OMIM] Type 1) exhibit increased tissue iron sec-
ondary to increased release of iron from intestinal cells and
macrophages.64 Patients with the disorder, even those with
unrecognized disease, are at increased risk for severe in-
fections with V vulnificus and Y enterocolitica.28,65 HFE-associ-
ated hemochromatosis has also been associated with
lymphocyte abnormalities, including reduced CD8+ T-
lymphocyte numbers (driven by reductions in the most
mature/differentiated effector memory T cells).66-68 It is
worth noting that there is no evidence that these
lymphocyte abnormalities influence infection risk, and at
the population level, HFE-associated hemochromatosis
does not affect survival.69 Increased risk for infection has
also been observed in cases of transfusional iron overload,
a potential consequence of repeated transfusions used to
manage inherited conditions such as thalassemia major,
sickle cell disease, and Diamond-Blackfan anemia.70
Infection is a major cause of death in this population,
and this risk has been associated with increased availability
of labile iron.70
Several parameters may limit the generalizability of
these data to the use of IV iron in patients with CKD. Both
the magnitude and duration of exposure to non-
–transferrin-bound iron likely affect the organ damage
observed in hereditary conditions.71 HFE-associated he-
reditary hemochromatosis can be associated with long-
term TSAT elevations (eg, >75%) and long-term expo-
sure to non–transferrin-bound iron.64,72,73 Such findings
are not generally observed with current IV iron use prac-
tices in the CKD population. Additionally, HFE-associated
hereditary hemochromatosis results in a parenchymal
deposition pattern of hepatic iron, not the reticuloendo-
thelial macrophage deposition pattern observed with IVKidney Med Vol 2 | Iss 3 | May/June 2020
Table 2. Relationship Between IV Iron Use and Infection Risk in Non-CKD Populations in Meta-analyses
Analysis Studies and Populations Included Comparison Results
Shah78 (2019) 6 RCTs conducted in adults admitted to
surgical intensive care unit (4 studies) or mixed
intensive care units (2 studies); N = 805
Iron vs no iron
(5 trials included
an IV iron arm)
No difference in risk for in-hospital infection; risk
ratio, 0.95 (95% CI, 0.79-1.19)
Shin79 (2019) 12 clinical studies of patients undergoing
orthopedic surgery; 4 RCTs (N = 616);
8 case-controlled studies (N = 1,253)
Perioperative IV
iron vs no IV iron
IV iron was associated with lower risk for
postoperative infection; risk ratio, 0.67 (95% CI,
0.49-0.91)
Shah80 (2018) 2 RCTs conducted in adults undergoing hip
fracture surgery; (N = 503)
IV iron vs control No difference in risk for infection; risk ratio, 0.99
(95% CI, 0.55-1.80)
Litton81 (2013) 72 RCTs conducted in renal (n = 19), obstetric
(n = 19), surgical (n = 11), oncology/
hematology (n = 11), cardiology (n = 4),
gastroenterology (n = 4), and other (n = 7)
settings; (total N = 10,605)
IV iron vs oral/no
iron
In 24 studies with data, IV iron was associated
with increased risk for all-cause infection;
relative risk, 1.33 (95% CI, 1.10-1.64); no
interaction between baseline ferritin, TSAT, iron
dose, or ESA use and risk for infection
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; IV, intravenous; RCT, randomized controlled trial; TSAT,
transferrin saturation.
Reviewiron or transfusion.1,74 The classic form of ferroportin
disease (OMIM Type 4A), a form of hereditary hemo-
chromatosis in which a ferroportin loss-of-function mu-
tation results in normal TSAT and a reticuloendothelial
iron deposition pattern, may be a better model for IV iron
use in CKD.1,75 Unfortunately, little is known about the
impact of ferroportin mutations on infection risk, and no
data exist regarding the epidemiology of infection among
patients with ferroportin disease.76
Evidence suggesting that hepatic distribution of iron
can affect clinical outcomes (including infection) was
observed in the Hepatitis C Anti-Viral Long-Term Treat-
ment to Prevent Cirrhosis (HALT-C) trial, in which the
presence of stainable iron in macrophages or portal
stromal cells was not associated with adverse clinical
outcomes, whereas higher baseline iron levels in hepa-
tocytes and portal triads was.77 Finally, differences in the
timing and magnitude of iron loading among inherited
diseases versus transfusional iron overload versus patients
with CKD receiving IV iron may further limit the
generalizability of findings from one disease state to
another.EXAMINING THE RISK FOR INFECTION
ASSOCIATED WITH IV IRON IN NON-CKD
STATES
IV iron is used in the management of anemia across
therapeutic areas and clinical settings. As detailed in
Table 2, the largest meta-analysis (which includes
studies in renal and nonrenal fields) demonstrates 33%
increased risk for all-cause infections following IV iron
administration, whereas 3 smaller meta-analyses with a
narrower scope indicate no association or even reduced
perioperative infections in the setting of IV iron sup-
plementation in patients undergoing orthopedic sur-
gery.78-81 Whereas the evidence surrounding the effect
of iron administered for therapeutic purposes is mixed,
iron deficiency has been consistently associated with
increased risk for infection.82 For example, a largeKidney Med Vol 2 | Iss 3 | May/June 2020prospective population-based study from Norway
demonstrated that TSAT ≤ 9% was associated with a 45%
increase in the incidence of bloodstream infections
(after adjustment for multiple demographic character-
istics and comorbid conditions).83OBSERVATIONAL STUDIES EXAMINING THE
RISK FOR INFECTION ASSOCIATED WITH IV
IRON IN CKD
To examine the relationship between IV iron administra-
tion and infection risk in the setting of CKD, we evaluated
both observational studies and RCTs. Although observa-
tional studies are prone to treatment selection bias and
residual confounding, thus limiting the ability to infer
causality and magnitude of effect, these studies can be used
for hypothesis generation. Potential biases include which
patients are prescribed iron, the formulation of iron
administered, dose of iron prescribed, and duration of
therapy. Other sources of confounding include achieved
iron status, hemoglobin levels, comorbid illness,
concomitant anemia therapies, and potential center effects.
When evaluating results of observational studies, it has
been suggested that weaker associations (eg, relative risk <
4) may be attributable to confounding.84,85
Observational data examining a potential association
between infection and IV iron are lacking in non–dialysis-
dependent CKD populations, and we were unable to
identify any relevant studies for this population. Data from
populations undergoing peritoneal dialysis are very
limited. In a single retrospective analysis of 61 patients
who received 2 doses of 500 mg of IV iron dextran and/or
iron sucrose, peritonitis rates were numerically (but not
statistically) greater in the 6 months after IV iron admin-
istration compared with the 6 months before therapy.86
At the time of the KDIGO Controversies Conference on
Iron Management in CKD,5 participants used the 2014
critical review by Ishida and Johansen87 as a starting point
for their evidence base. That review concluded, “Overall,
the current body of literature appears to favor an345
Table 3. Relationship Between IV Iron Use and/or Higher Ferritin Levels and Infection Risk in HD Populations (observational studies
from 2014 and later)
Study Population Examined Comparison Results
Bailie88
(2015)
32,435 patients receiving IV
iron in 12 countries (median
follow-up, 1.7 y)
100-199 mg/mo (average) IV iron vs
other dosing categories (ie, 0, 1-99, 200-
299, 300-399, and ≥400 mg/mo
[average])
No significant differences in infection-
related mortality (vs reference group)
Tangri89
(2015)
9,544 incident HD patients in
US (median follow-up, 23 mo)
6-mo iron exposure of 1-900 mg vs other
dosing categories (ie, 0, 901-2,100, and
>2,100 mg/6 mo); 1- and 3-mo iron
exposure analyses also conducted
No significant differences in infection-
related hospitalization by dose across
any of the IV iron exposure windows
Zitt90
(2014)
235 incident dialysis patients
(HD: n = 197; peritoneal
dialysis: n = 38) in Austria
(median follow-up, 34 mo)
Iron supplementation (IV, 81%; oral, 6%)
vs no iron supplementation (13%)
Iron supplementation was associated
with reduced sepsis-related mortality;
HR, 0.31 (95% CI, 0.09-1.04)
Kuragano91
(2014)
1,086 patients on maintenance
HD in Japan (2-y follow-up)
High (≥50 mg/wk) or low IV iron (<50
mg/wk) vs no iron; ferritin consistently
below the standard vs other ferritin
categories (ie, high ferritin group, low-to-
high ferritin group, high-to-low ferritin
group, and fluctuating ferritin group)
Both IV iron cohorts were associated
with increased risk for infection (vs no
iron); HR, 1.78 (95% CI, 1.04-3.05) for
low IV iron; HR, 5.22 (95% CI, 2.25-
12.14) for high IV iron; high ferritin levels
were associated with increased risk for




22,820 adults on HD and
history of IV iron use
hospitalized for bacterial
infection
In-hospital IV iron vs no in-hospital IV iron Receipt of in-hospital IV iron was not
associated with adverse outcomes (ie,
30-d mortality, length of stay, or 30-
d readmission)
Li94 (2019) 13,249 HD patients in the US
receiving IV iron with 1 of 5
prespecified administration
strategies
4 IV iron dosing strategies (ie, least
intensive, less intensive, more intensive,
and most intensive) vs reference dosing
strategy
The “more” and “most” intensive
strategies were associated with higher
risk for infection-related events (ie,
infection-related hospitalization or
infection-related death); 60-d risk
difference for “most” intensive strategy:
1.8% (95% CI, 1.2%-2.6%); 60-d risk
difference for “more” intensive strategy:
0.8% (95% CI, 0.3%-1.3%)
Yen96
(2019)
1,410 incident HD adults in
Taiwan with any infectious
disease requiring IV antibiotics
Iron use during the 4-wk case period vs
iron use during 3 control periods for each
patient
No significant difference in odds of
receiving iron during the case period.
Similar results in subgroup analyses for
diabetes, heart failure, chronic lung
disease, catheter use, and >300 mg/mo
iron
Abbreviations: CI, confidence interval; HD, hemodialysis; HR, hazard ratio; IV, intravenous; US, United States.
Reviewassociation between iron and infection in hemodialysis
patients, though several limitations must be acknowledged
and publication bias cannot be ruled out.”87(p34) Mac-
dougall et al5 subsequently identified 4 additional obser-
vational studies for their assessment. Three of those
studies88-90 found no increase in either infection-related
mortality or hospitalization with IV iron use or higher
ferritin concentrations, whereas 1 study91 demonstrated a
significant risk. After the KDIGO Controversies Conference
was held, Ishida et al92 published an observational study
suggesting that in-hospital administration of IV iron was
not associated with adverse outcomes among HD patients
hospitalized for bacterial infection. In a 2018 meta-analysis
of data from 8 observational trials (including many of
those described), risk for infection was comparable be-
tween higher-dose IV iron (ie, >200 mg per month) and
lower-dose IV iron/oral iron/no iron (HR, 1.13; 95% CI,
0.99-1.28).93346A large US cohort study (N = 13,249) demonstrated
increased risk for infection-related events and infection-
related mortality with more intense IV iron dosing stra-
tegies.94 It should be noted that as part of the reference
strategy, patients received ≥25 mg of IV iron weekly,
provided that TSAT was ≤50%, ferritin levels were ≤1,200
ng/mL, and all dosing strategies were more intensive than
those assessed in the PIVOTAL study (discussed later).94,95
Additionally, a sizeable proportion of patients deviated
from their index dosing strategy during follow-up.
Most recently, a retrospective case-crossover study in
Taiwan found no evidence of increased infection risk
associated with IV iron therapy (20.1% of the study cohort
received IV iron; 8.6% of the study cohort received >300
mg of iron per month) among incident HD patients. The
lack of an association was consistent across iron doses,
catheter use, and comorbid conditions.96 These studies are
summarized in Table 3.Kidney Med Vol 2 | Iss 3 | May/June 2020
Table 4. RCTs Examining the Infection-Related Safety of IV Iron in Non–Dialysis-Dependent CKD Populations (from 2008 and later)






≥12 y old with ND-CKD;
eGFR ≤ 45 mL/min/1.73 m2;
Hb ≤ 11 g/dL; TSAT ≤ 25%;
ferritin ≤ 300 μg/L; fixed
ESA dose (if applicable)
255 Up to 3 infusions of ferric
carboxymaltose (up to 1,000
mg at d 1; 2 additional doses
[up to 500 mg] if TSAT < 30%
and ferritin < 500 ng/mL); oral
ferrous sulfate, 325 mg, 3×/d
8 wk Similar rates of infection-related
adverse events (including
bronchitis, upper respiratory






>18 y old with ND-CKD;
eGFR > 20 and ≤60 mL/
min/1.73 m2; Hb, 8-12 g/dL;
ferritin < 100 μg/L or
TSAT < 25%
136 IV iron sucrose, 200 mg, at wk
0, 2, 4, 6, and 8; oral ferrous





adverse events occurred more
commonly in the IV iron group
(adjusted IRR, 2.12 [95% CI,
1.24-3.64]); lung and skin
infections 3- to 4-fold more




≥18 y old with ND-CKD;
eGFR ≤ 60 mL/min/1.73 m2;
Hb, 9-11 g/dL; ferritin < 100
μg/L (or <200 μg/L +
TSAT ≤20%); ESA naive
626 High-dose ferric
carboxymaltose (ferritin target,
400-600 μg/L); low-dose ferric
carboxymaltose (ferritin target,
400-600 μg/L); oral ferrous
sulfate, 100 mg, 2×/d
56 wk Similar rates of infection and
serious infection between
groups
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; FIND-CKD,
Ferinject Assessment in Patients With Iron Deficiency Anaemia and Non-Dialysis-Dependent Chronic Kidney Disease; Hb, hemoglobin; IRR, incidence rate ratio;
IV, intravenous; ND-CKD, non–dialysis-dependent chronic kidney disease; RCT, randomized controlled trial; REVOKE, Randomized Trial to Evaluate Intravenous and
Oral Iron in Chronic Kidney Disease; TSAT, transferrin saturation.
ReviewObservational studies have also examined the effects of
dosing strategies and IV iron formulations on infection
risk. In a large retrospective cohort, Brookhart et al97 found
that HD patients receiving bolus dosing of IV iron
(ie, ≥100 mg iron during ≥2 consecutive HD sessions)
were at increased risk for infection-related hospitalization
relative to patients receiving lower maintenance dosing of
IV iron. In that analysis, patients receiving bolus dosing
were administered a median of 700 mg per month of IV
iron compared with 200 mg per month in the mainte-
nance group. The risk for infection associated with
maintenance dosing was similar to that observed among
patients receiving no iron. There is a relative dearth of
studies examining the effects of different iron formulations
on infection risk, and the results of the few available
studies are conflicting and therefore inconclusive.98-100CLINICALTRIALS EXAMINING INFECTION RISK
ASSOCIATED WITH IV IRON IN PATIENTS WITH
CKD
In 2008, a meta-analysis compared the safety and efficacy
of IV iron relative to oral iron in non–dialysis-dependent
patients with CKD, but no data were available regarding
infections in any of the 6 included RCTs.101 Since that
analysis, 3 RCTs with infection-related end points have
been published.102-104 The study designs and (discordant)
findings of these trials are summarized in Table 4. A meta-
analysis of these 3 trials reveals similar risk for infection
between patients receiving IV iron and those receiving oral
iron (risk ratio, 1.31; 95% CI, 0.89-1.92).105 Of the 3
trials, the one that demonstrated an increased risk forKidney Med Vol 2 | Iss 3 | May/June 2020infection with IV iron, REVOKE (Randomized Trial to
Evaluate Intravenous and Oral Iron in CKD), included an 8-
week treatment period and a 2-year follow-up period.103
In the first 3 months of the trial (ie, treatment plus
1 month of additional follow-up), the number of
patients with infection was higher in the oral iron arm
than in the IV iron arm (6 vs 3).
Until 2018, RCT data examining the effects of IV iron
on infection risk among patients on kidney replacement
therapy were relatively scarce. A 2018 systematic review
and meta-analysis examining the safety of IV iron in
dialysis included infection data for only 4 studies (N =
743); 1 was conducted in patients receiving peritoneal
dialysis and 3 examined HD populations. Overall, re-
searchers determined that “higher doses” (the definition
varied by study) of IV iron were not associated with
increased risk for infection (HR, 1.02; 95% CI, 0.74-
1.41).93 Although reassuring, results of the included
studies and the meta-analysis should be viewed in light of
numerous limitations. The study populations were
generally small, with only 1 trial randomly assigning more
than 100 patients.93,106 The definition of “higher doses”
of IV iron varied greatly; in the study of (oral) ferric citrate
by Lewis et al,106 “higher doses” of iron equated to a
median weekly dose of w27 mg. The duration of follow-
up across studies varied from 6 to 52 weeks, and each
study used different formulations of IV iron.93 Most
notably, each study targeted (or allowed) dissimilar TSAT
and/or ferritin level cutoffs.
The PIVOTAL trial, conducted over nearly 5 years, was
designed to compare the safety and efficacy of 2 iron









IV Iron Sucrose 
(N=1,048) 
n (%) Hazard or Rate Ratio (95% CI) P Value
Hospitalization for infection 323 (29.6) 307 (29.3) 0.99 (0.82-1.16) 0.92
Infection episodes 63.3 per 100 PY
69.4 
per 100 PY 0.91 (0.79-1.05) N/A
1.3 1.40.8 0.9 1.0 1.1 1.2
Proactive, High-Dose Better Reactive, Low-Dose Better
Figure 2. Infection end points in the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial. Based on data in Macdou-
gall et al.95 Abbreviations: CI, confidence interval; IV, intravenous; N/A, not available; PY, patient-years.
Safety suggested (eg, DRIVE)109
Risk suggested in some observational studies* (eg, Li et al)94
~700 μg/L ~1200 μg/L
Reviewhigher-dose regimen and a reactive lower-dose regimen.95
Incident HD (<12 months) patients were eligible to
participate if they had a ferritin concentration < 400 μg/L,
had a TSAT < 30%, and were receiving treatment with an
erythropoiesis-stimulating agent (ESA). Patients randomly
assigned to the high-dose group (n = 1,093) received 400
mg of IV iron sucrose monthly (unless ferritin level was
>700 μg/L or TSAT was ≥40%) and patients in the low-
dose group (n = 1,048) received enough IV iron (up to
400 mg monthly) to maintain ferritin concentrations ≥
200 μg/L and TSATs ≥ 20%. Iron was temporarily with-
held if patients developed an active infection. Most patients
were followed up for at least 2 years, and across the trial,
median monthly doses of IV iron were 264 and 145 mg in
the high- and low-dose groups, respectively. By month 12,
patients in the high-dose group received w2 g more iron
than patients in the control group.
Although the primary end point in the PIVOTAL trial
was cardiovascular, infection-related outcomes were
included as safety end points.95 As detailed in Figure 2,
random assignment to the proactive group with higher-
dose IV iron did not lead to increased risk for infection
or hospitalization for infection. Infection was identified as
a cause of death in 4.3% of patients receiving high-dose
iron and 3.9% of patients receiving low-dose iron. In a
prespecified secondary analysis, no association between
iron dose, serum ferritin level, or TSAT and infection risk






Figure 3. Safety of administering intravenous (IV) iron to hemo-
dialysis patients by ferritin concentration (based on available ev-
idence). Eligibility criteria for each of the cited studies differ and
may affect generalizability of the results to broader populations.
*Results of observational studies should be viewed cautiously
because weaker associations may be attributable to confound-
ing. Abbreviations: DRIVE, Dialysis Patients’ Response to IV
Iron with Elevated Ferritin; PIVOTAL, Proactive IV Iron Therapy
in Haemodialysis Patients; RCT, randomized controlled trial.CLINICAL IMPLICATIONS AND AREAS OF
UNCERTAINTY
The host and pathogens are engaged in a tug of war for
iron; microbes expend considerable resources to secure
iron and in turn, our immune system strives to restrict iron
availability.107 Although there is a plausible connection
between iron use and infection, available clinical data
largely fail to demonstrate an association between IV iron
use and infection risk among patients with CKD. None-
theless, the decision to administer IV iron to a patient with
CKD requires consideration of iron- and patient-related
factors and should include an individualized assessment
of risk versus benefit. In addition to considering the risks348and benefits of iron therapy, one must consider the risks
and benefits of not administering iron, such as the impact
of persistent iron deficiency or anemia and risks associated
with other therapies (eg, blood transfusions or higher ESA
doses). For patients with chronic or latent infections,
microbe-related factors should also be considered.
Some of the clinical benefits of IV iron in the CKD
population are well established; it can help correct iron
deficiency anemia, resulting in increased hemoglobin
concentration while reducing the need for ESAs. In the HD
population, the PIVOTAL trial demonstrated that a proac-
tive approach to iron therapy (within the limits tested)
resulted in significantly and meaningfully improved pa-
tient outcomes, as assessed by time to all-cause death,
myocardial infarction, stroke, or hospitalization for heart
failure.95 By contrast, in the non–dialysis-dependent CKD
population, the impact of IV iron on “hard” outcomes
remains ill-defined.
In an incident HD population with ferritin concentra-
tions up to 700 μg/L, the high-dose IV iron regimen tested
in the PIVOTAL trial did not demonstrate any evidence of
harm related to infection.95 The mechanisms underlying
these results have not been fully elucidated, and severalKidney Med Vol 2 | Iss 3 | May/June 2020
• Sepsis
• Bacteremia 
• Serious localized infection
• Receiving treatment for 
acute infection
• No signs of infection
• Isolated ↑ CRP
• HIV with viral suppression
• Stable/chronic steroid use
• Latent TB (post-INH)
• Minor localized infections







• Moderate localized infections (eg, bronchitis)
• Being treated for Helicobacter pylori
• PPD+ (no workup or treatment)
Figure 4. Deciding whether to administer intravenous iron to hemodialysis patients with iron deficiency. Guidance based on expert
opinion and assumes iron deficiency secondary to chronic kidney disease and noncritical hemoglobin concentration. Abbreviations:
CRP, C-reactive protein; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INH, isoniazid; PPD+, positive purified protein
derivative skin test; TB, tuberculosis.
Reviewhypotheses exist. Many patients in the low-dose group met
criteria for iron deficiency and/or anemia, which may it-
self be associated with increased risk for infection.82,95
Patients in the low-dose arm also required significantly
higher ESA doses, and recent data suggest that erythro-
poietin can enhance the growth of some bacteria (eg, E coli
and S aureus).108 Although PIVOTAL has added greatly to
the evidence base, several unanswered questions remain.
For instance, it remains uncertain whether the infection-
related results of the PIVOTAL trial can be generalized
to: (1) non–dialysis-dependent CKD populations, (2) pa-
tients receiving peritoneal dialysis, (3) prevalent HD
populations, (4) other iron formulations, (5) patients with
ferritin levels > 700 μg/L, (6) patients not receiving ESAs,
or (7) patients treated with hypoxia-inducible factor prolyl
hydroxylase inhibitors. These issues notwithstanding, the
available high-quality evidence supports an approach to IV
iron dosing that permits, if not encourages, ferritin levels
to reach w700 μg/L in HD patients. Such an approach
appears to confer clinical benefit without increased risk for
harm (eg, infections). Data examining infection risk
among patients with greater iron stores (as assessed by
ferritin levels of 700-1,200 μg/L) are varying,94,109 and
there are no data examining the safety of IV iron admin-
istered to HD patients with ferritin levels > 1,200 μg/L
(Fig 3). Beyond ferritin, TSAT should also be weighed into
the decision to administer (or withhold) IV iron. Based on
the PIVOTAL trial, IV iron can be safely administered to
patients with TSATs < 40%. This is consistent with phys-
iologic data suggesting that the risk for a resultant (after IV
iron administration) TSAT level associated with more than
transient non–transferrin-bound iron generation is low
with baseline TSATs < 40%.
Consistent with prior recommendations, it remains
prudent to avoid IV iron for the treatment of anemia in
CKD in the setting of active systemic infection.110 The
need to administer IV iron in the setting of anemia in CKD
is rarely urgent and can generally be delayed until the
infection subsides, avoiding the hypothetical risk for acute
exacerbation of the infection. Additionally, in the settingKidney Med Vol 2 | Iss 3 | May/June 2020of acute infection, the beneficial effects of IV iron are likely
hindered by the effects of hepcidin and the sequestration
of iron in storage cells. The optimal iron strategy for pa-
tients with CKD and chronic infections such as human
immunodeficiency virus and hepatitis C, both of which
can coexist and/or contribute to CKD, is less clear.111,112
Last, using ferritin levels to guide IV iron dosing can be
challenging during an infection because ferritin is an
acute-phase reactant. In the absence of evidence-based
guidance, there are a number of clinical scenarios for
which the decision to administer iron should be carefully
considered (Fig 4). Independent of the administration (or
withholding) of IV iron, clinicians should continue efforts
to reduce the risk for infection among patients with CKD,
including evidence-based vaccination, minimization of
catheter use, increased surveillance, and implementation of
infection control procedures.
CONCLUSIONS
A multidisciplinary appraisal of the evidence confirms
biological plausibility for an association between IV iron
use and increased infection risk among patients with CKD.
In the absence of an urgent need to treat anemia in CKD,
there is little reason to administer IV iron to patients
experiencing an acute infection. However, a growing ev-
idence base of clinical data suggests that a judicious but
proactive approach to the use of IV iron in CKD (similar to
the 400–mg per month arm in the PIVOTAL trial) is not
associated with a clinically meaningful increased risk for
infection. Furthermore, the management of iron deficiency
in patients with CKD appears to confer non–infection-
related benefits that should be factored into clinical deci-
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